ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing February 25, 2026 VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen February 25, 2026 94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval
Extend Launches CIP: a Cultural Intelligence Platform Empowering Marketers to Plan, Manage, and Monitor Campaigns Directly Through Its Marketing Platform February 25, 2026 Extend CIP unifies years of product and agency experience into a single platform for marketers across the Arab world, launching with the region's largest influencer ad library and end-to-end campaign tools
Orbia Announces CFO Transition and Appointment of Successor February 25, 2026 Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) (“Orbia” or “the Company”) announced today that James P. “Jim” Kelly will retire as Chief Financial Officer after four years of service. The Company also announced that Cristian “Cape” Capellino will assume the role of Chief Financial Officer effective March 15, 2026. Kelly joined Orbia in 2021 [...]
Airspan Networks Expands 5G In-Motion Platform into Defense MANET, High-Altitude Platforms, and Drones February 25, 2026 Introducing a resilient advanced communications bridge between terrestrial and aerial networks
NYU Abu Dhabi and RTW Investments Announce Strategic Collaboration to Advance Healthcare and Life Sciences Innovation February 25, 2026 Partnership will deliver executive programs and convene global investors, policymakers, and experts to strengthen the region’s healthcare ecosystem
Aera Technology Named to The Hackett Group® 2025–2026 “50 to Watch” List for Procurement Innovation February 25, 2026 Recognized for Enabling Real-Time Procurement Decisions Across the Enterprise
Alkermes plc Announces CEO Succession Plan February 25, 2026 — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors —
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 February 25, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast [...]
Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases February 25, 2026 Partnership to use Chemify’s programmable chemistry technology and Sanacor’s translational biology expertise to accelerate small-molecule discovery addressing mitochondrial dysfunction
